Alkem Laboratories Ltd (NSE: ALKEM) and Gland Pharma Limited (NSE: GLAND) are both listed in the Medicinal Chemicals and Botanical Products industry. Alkem Laboratories has a market capitalisation of ₹61,636 Cr and Gland Pharma ₹50,589 Cr, as of 9 Nov 2026. Their P/E ratios are 26.8 and 49.2 respectively. Return on equity is 17.56% for Alkem Laboratories and 10.53% for Gland Pharma. Over one year, Alkem Laboratories's share price is down 2.0% and Gland Pharma's is up 70.3%.
| Metric | Alkem Laboratories | Gland Pharma |
|---|---|---|
| NSE Symbol | ALKEM | GLAND |
| BSE Code | 539523 | 543245 |
| Share Price | ₹5,398.50 | ₹3,285.00 |
| Market Cap | ₹61,636 Cr | ₹50,589 Cr |
| P/E Ratio | 26.8 | 49.2 |
| Return on Equity | 17.56% | 10.53% |
| Return on Assets | 8.43% | 6.27% |
| Dividend Yield | 0.39% | 0.65% |
| Beta (1Y) | 0.29 | 0.49 |
| 1-Year Price Change | -2.0% | +70.3% |
| 3-Month Price Change | -3.6% | +23.2% |
| 52-Week Range | ₹4,811.00 – ₹5,933.50 | ₹1,573.60 – ₹3,374.00 |
| Latest Quarter | Q1 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹3,740 Cr | ₹1,834 Cr |
| Quarterly Net Profit | ₹521 Cr | ₹291 Cr |
| Net Margin | 13.9% | 15.9% |
| EPS (Basic, Quarter) | ₹43.49 | ₹17.62 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Hyderabad, Telangana |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neu…
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, g…
Alkem Laboratories has a market capitalisation of ₹61,636 Cr, against ₹50,589 Cr for Gland Pharma as of 9 Nov 2026, about 1.2 times the size by market cap.
Alkem Laboratories has a P/E of 26.8 and Gland Pharma a P/E of 49.2 as of 9 Nov 2026.
Alkem Laboratories has a return on equity of 17.56% and Gland Pharma 10.53%.
Alkem Laboratories's share price is down 2.0% over one year and Gland Pharma's is up 70.3%.
Alkem Laboratories reported revenue of ₹3,740 Cr and net profit of ₹521 Cr for Q1 FY27. Gland Pharma reported revenue of ₹1,834 Cr and net profit of ₹291 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.